Drug Development

Sanofi, NIH create a three-pronged antibody to target HIV; Akari soars on PhIII plans; Juno plots planned $225M raise


⇨ A collaboration between Sanofi and the NIH led to the development of a three-pronged antibody that has shown promise in a primate model for HIV. The therapy binds to three different sites on the virus, which makes it harder for HIV to escape. The investigators are now planning human trials to see how this could work in patients.

⇨ Shares of Akari $AKTX shot up more than 80% Thursday morning as investors reacted to their plans to launch a Phase III program. The biotech has been under a cloud since it was forced to restate responses tracked in an early-stage study, triggering the abrupt exit of its CEO.

⇨ You can add one more new biotech role for ex-GSK CEO Andrew Witty. The former pharma chief has joined the advisory board at Synthego, a genome engineering outfit based in Redwood City, CA. This is Witty’s second board position, after G1, and it arrives on the heels of the announcement that he’s joining Hatteras as a partner.

⇨ Seattle-based Juno Therapeutics $JUNO is raising $225 million in a follow-on offering.

Cellectar Biosciences $CLRB and Onconova Therapeutics entered into a strategic collaboration to develop new phospholipid drug conjugates combining Cellectar’s patented phospholipid ether delivery platform with select proprietary compounds or payloads from Onconova’s early stage product pipeline.

⇨ Cambridge, MA-based AvroBio is expanding its pipeline with a third program for a gene therapy for Pompe disease.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biomanufacturing